Literature DB >> 4087000

Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

A Vincent, J Newsom-Davis.   

Abstract

Anti-acetylcholine receptor (AChR) antibody was undetectable in 26/153 (17%) sera from myasthenia gravis patients assayed by standard RIA using human acetylcholine receptor. Eight of these were found to be positive with a modified protocol using a mixture of normal and denervated AChR, reducing the proportion of "negative" sera to 12%. Many of these were from patients with a short history; two such patients later developed low positive values. Anti-AChR without clinical evidence of myasthenia was found in one of three monozygotic twins of myasthenia gravis patients, and in one of thirty other first degree relatives of a further 17 patients. Anti-AChR is a valuable and highly specific diagnostic test which, with the assay used here, is positive in about 88% of patients with clinical features of myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087000      PMCID: PMC1028609          DOI: 10.1136/jnnp.48.12.1246

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  29 in total

1.  Anti-acetycholine receptor antibodies in penicillamine treated patients without myasthenia gravis.

Authors:  V M Martin; A Vincent; C Clarke
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

2.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.

Authors:  D A Compston; A Vincent; J Newsom-Davis; J R Batchelor
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

Review 3.  Immunology of acetylcholine receptors in relation to myasthenia gravis.

Authors:  A Vincent
Journal:  Physiol Rev       Date:  1980-07       Impact factor: 37.312

4.  Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases.

Authors:  A Vincent; S G Cull-Candy; J Newsom-Davis; A Trautmann; P C Molenaar; R L Polak
Journal:  Muscle Nerve       Date:  1981 Jul-Aug       Impact factor: 3.217

5.  Acetylcholine receptor antibodies in myasthenia gravis.

Authors:  P Kornfeld; J Nall; H Smith; T W Mittag; A N Bender; E P Ambinder; S H Horowitz; A E Papatestas; H Gross; G Genkins
Journal:  Muscle Nerve       Date:  1981 Sep-Oct       Impact factor: 3.217

6.  Myasthenia gravis: antibodies to acetylcholine receptor in ocular myasthenia gravis.

Authors:  K Oda; Y Ito
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

7.  Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations.

Authors:  R S Tindall
Journal:  Ann Neurol       Date:  1981-11       Impact factor: 10.422

8.  Antibodies to acetylcholine receptor in patients with thymoma but without myasthenia gravis.

Authors:  S Cuénoud; T E Feltkamp; B W Fulpius; H J Oosterhuis
Journal:  Neurology       Date:  1980-02       Impact factor: 9.910

9.  Myasthenia gravis: antibodies to acetylcholine receptor with human and rat antigens.

Authors:  K Oda; I Goto; Y Kuroiwa; K Onoue; Y Ito
Journal:  Neurology       Date:  1980-05       Impact factor: 9.910

10.  Comparison of antigenic sources for acetylcholine receptor antibody assays in myasthenia gravis.

Authors:  M W McAdams; A D Roses
Journal:  Ann Neurol       Date:  1980-07       Impact factor: 10.422

View more
  79 in total

Review 1.  The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.

Authors:  M Jallouli; D Saadoun; B Eymard; G Leroux; J Haroche; D Le Thi Huong; C De Gennes; C Chapelon; O Benveniste; B Wechsler; P Cacoub; Z Amoura; J C Piette; N Costedoat-Chalumeau
Journal:  J Neurol       Date:  2011-12-08       Impact factor: 4.849

Review 2.  Juvenile myasthenia: diagnosis and treatment.

Authors:  B Anlar
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

3.  Immunoglobulin heavy chain gene associations in myasthenia gravis: new evidence for disease heterogeneity.

Authors:  A Demaine; N Willcox; M Janer; K Welsh; J Newsom-Davis
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

4.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

Review 5.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

6.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Authors:  Chengyong Shen; Yisheng Lu; Bin Zhang; Dwight Figueiredo; Jonathan Bean; Jiung Jung; Haitao Wu; Arnab Barik; Dong-Min Yin; Wen-Cheng Xiong; Lin Mei
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

7.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

Review 8.  Update on myasthenia gravis.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

9.  Antibodies against saline-soluble components of skeletal muscle in myasthenia gravis.

Authors:  A Komiyama; I Kamo; S Furukawa; S Akazawa; K Hirayama; E Satoyoshi
Journal:  J Neurol       Date:  1988-03       Impact factor: 4.849

10.  3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.

Authors:  J Palace; C M Wiles; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.